The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Meningococcal Group B Vaccine Market Research Report 2024
Synopsis
Meningococcal B vaccine can help protect against meningococcal disease caused by serogroup B.
The global Meningococcal Group B Vaccine market was valued at US$ 1107 million in 2023 and is anticipated to reach US$ 2034.2 million by 2030, witnessing a CAGR of 8.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Meningococcal Group B Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meningococcal Group B Vaccine.
Report Scope
The Meningococcal Group B Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Meningococcal Group B Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Meningococcal Group B Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Pfizer
Segment by Type
Bexsero
Trumenba
Other
Segment by Application
Public
Private
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Meningococcal Group B Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Meningococcal Group B Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Meningococcal B vaccine can help protect against meningococcal disease caused by serogroup B.
The global Meningococcal Group B Vaccine market was valued at US$ 1107 million in 2023 and is anticipated to reach US$ 2034.2 million by 2030, witnessing a CAGR of 8.6% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Meningococcal Group B Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meningococcal Group B Vaccine.
Report Scope
The Meningococcal Group B Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Meningococcal Group B Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Meningococcal Group B Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Pfizer
Segment by Type
Bexsero
Trumenba
Other
Segment by Application
Public
Private
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Meningococcal Group B Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Meningococcal Group B Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Meningococcal Group B Vaccine Market Overview
1.1 Product Overview and Scope of Meningococcal Group B Vaccine
1.2 Meningococcal Group B Vaccine Segment by Type
1.2.1 Global Meningococcal Group B Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Bexsero
1.2.3 Trumenba
1.2.4 Other
1.3 Meningococcal Group B Vaccine Segment by Application
1.3.1 Global Meningococcal Group B Vaccine Market Value by Application: (2024-2030)
1.3.2 Public
1.3.3 Private
1.4 Global Meningococcal Group B Vaccine Market Size Estimates and Forecasts
1.4.1 Global Meningococcal Group B Vaccine Revenue 2019-2030
1.4.2 Global Meningococcal Group B Vaccine Sales 2019-2030
1.4.3 Global Meningococcal Group B Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Meningococcal Group B Vaccine Market Competition by Manufacturers
2.1 Global Meningococcal Group B Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Meningococcal Group B Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Meningococcal Group B Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Meningococcal Group B Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Meningococcal Group B Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Meningococcal Group B Vaccine, Product Type & Application
2.7 Meningococcal Group B Vaccine Market Competitive Situation and Trends
2.7.1 Meningococcal Group B Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Meningococcal Group B Vaccine Players Market Share by Revenue
2.7.3 Global Meningococcal Group B Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Meningococcal Group B Vaccine Retrospective Market Scenario by Region
3.1 Global Meningococcal Group B Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Meningococcal Group B Vaccine Global Meningococcal Group B Vaccine Sales by Region: 2019-2030
3.2.1 Global Meningococcal Group B Vaccine Sales by Region: 2019-2024
3.2.2 Global Meningococcal Group B Vaccine Sales by Region: 2025-2030
3.3 Global Meningococcal Group B Vaccine Global Meningococcal Group B Vaccine Revenue by Region: 2019-2030
3.3.1 Global Meningococcal Group B Vaccine Revenue by Region: 2019-2024
3.3.2 Global Meningococcal Group B Vaccine Revenue by Region: 2025-2030
3.4 North America Meningococcal Group B Vaccine Market Facts & Figures by Country
3.4.1 North America Meningococcal Group B Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Meningococcal Group B Vaccine Sales by Country (2019-2030)
3.4.3 North America Meningococcal Group B Vaccine Revenue by Country (2019-2030)
3.4.4 the United States
3.4.5 Canada
3.5 Europe Meningococcal Group B Vaccine Market Facts & Figures by Country
3.5.1 Europe Meningococcal Group B Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Meningococcal Group B Vaccine Sales by Country (2019-2030)
3.5.3 Europe Meningococcal Group B Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Meningococcal Group B Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Meningococcal Group B Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Meningococcal Group B Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Meningococcal Group B Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Meningococcal Group B Vaccine Market Facts & Figures by Country
3.7.1 Latin America Meningococcal Group B Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Meningococcal Group B Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Meningococcal Group B Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Meningococcal Group B Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Meningococcal Group B Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Meningococcal Group B Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Meningococcal Group B Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Meningococcal Group B Vaccine Sales by Type (2019-2030)
4.1.1 Global Meningococcal Group B Vaccine Sales by Type (2019-2024)
4.1.2 Global Meningococcal Group B Vaccine Sales by Type (2025-2030)
4.1.3 Global Meningococcal Group B Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Meningococcal Group B Vaccine Revenue by Type (2019-2030)
4.2.1 Global Meningococcal Group B Vaccine Revenue by Type (2019-2024)
4.2.2 Global Meningococcal Group B Vaccine Revenue by Type (2025-2030)
4.2.3 Global Meningococcal Group B Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Meningococcal Group B Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Meningococcal Group B Vaccine Sales by Application (2019-2030)
5.1.1 Global Meningococcal Group B Vaccine Sales by Application (2019-2024)
5.1.2 Global Meningococcal Group B Vaccine Sales by Application (2025-2030)
5.1.3 Global Meningococcal Group B Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Meningococcal Group B Vaccine Revenue by Application (2019-2030)
5.2.1 Global Meningococcal Group B Vaccine Revenue by Application (2019-2024)
5.2.2 Global Meningococcal Group B Vaccine Revenue by Application (2025-2030)
5.2.3 Global Meningococcal Group B Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Meningococcal Group B Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Meningococcal Group B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GSK Meningococcal Group B Vaccine Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Meningococcal Group B Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Meningococcal Group B Vaccine Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Meningococcal Group B Vaccine Industry Chain Analysis
7.2 Meningococcal Group B Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Meningococcal Group B Vaccine Production Mode & Process
7.4 Meningococcal Group B Vaccine Sales and Marketing
7.4.1 Meningococcal Group B Vaccine Sales Channels
7.4.2 Meningococcal Group B Vaccine Distributors
7.5 Meningococcal Group B Vaccine Customers
8 Meningococcal Group B Vaccine Market Dynamics
8.1 Meningococcal Group B Vaccine Industry Trends
8.2 Meningococcal Group B Vaccine Market Drivers
8.3 Meningococcal Group B Vaccine Market Challenges
8.4 Meningococcal Group B Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
